Elocalcitol

Elocalcitol (BXL-628), a vitamin D analogue, is a selective, orally active vitamin D receptor (VDR) agonist. Elocalcitol shows anti-inflammatory activity. Elocalcitol inhibits growth of prostate cancer cells[1][2].

Product Specifications

CAS Number

[199798-84-0]

Product Name Alternative

BXL-628; Ro-26-9228

UNSPSC

12352211

Target

Apoptosis; VD/VDR

Type

Reference compound

Related Pathways

Apoptosis; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Endocrinology; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/elocalcitol.html

Purity

99.2

Solubility

DMSO : 30 mg/mL (ultrasonic; warming)

Smiles

C[C@@]12[C@](CC=C2[C@@H](C)C/C=C/C(CC)(O)CC)([H])/C(CCC1)=C/C=C3C([C@H](C[C@@H](C\3)O)F)=C

Molecular Formula

C29H43FO2

Molecular Weight

442.65

References & Citations

[1]Mariani M, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012 Jul;27 (7) :2010-9. |[2]Marchiani S, et al. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol. 2006 Jun;132 (6) :408-16.